GlassScriptPhysician profile
Robert Joel Rosser
NPI 1912991605
$1,305.40
in general payments reported to CMS, 2019-2025
27 companies · $394 in 2025
The $394 reported for 2025 was more than what 85% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $28.82 · 2021: $78.23 · 2022: $280 · 2023: $173 · 2024: $247 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $180.48 | 2019-2025 | Darzalex, Talvey, Erleada |
| Telix Pharmaceuticals | $147.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $97.28 | 2025 | Imfinzi |
| Array Biopharma INC | $65.28 | 2019-2025 | Mektovi, Braftovi |
| Pfizer INC. | $64.16 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $62.98 | 2024-2025 | Libtayo |
| Genzyme Corporation | $57.35 | 2021-2022 | |
| Sobi, INC | $56.04 | 2023 | |
| Astellas Pharma US INC | $54.53 | 2025 | Vyloy, Xtandi |
| Ge Healthcare | $48.38 | 2025 | |
| Lilly USA, LLC | $47.58 | 2022-2023 | Jaypirca, Retevmo |
| Blueprint Medicines Corporation | $40.66 | 2022-2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $39.66 | 2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $38.60 | 2019-2021 | |
| Taiho Oncology, INC. | $32.92 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $32.81 | 2024 | Besremi |
| Karyopharm Therapeutics INC. | $32.24 | 2024 | Xpovio |
| Incyte Corporation | $25.96 | 2025 | Jakafi |
| Aveo Pharmaceuticals, INC. | $23.94 | 2024 | |
| Eisai INC. | $23.92 | 2023 | |
| Deciphera Pharmaceuticals INC. | $22.51 | 2025 | Qinlock, Tgct |
| Ortho-Clinical Diagnostics, INC. | $21.05 | 2021 | |
| Daiichi Sankyo INC. | $20.90 | 2019 | |
| Amgen INC. | $20.84 | 2023 | Nplate, Xgeva |
| Eusa Pharma (US) LLC | $20.05 | 2019 | |
| Puma Biotechnology, INC. | $16.65 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.